Pingyangmycin is a new species of bleomycin class antitumor drug, which is developed independently by our scholars and is widely used in the treatment of hemangioma and vascular malformation. It is a cytotoxic glycopeptide anti-tumor antibiotic, which can promote the oxidation of Fe2+ to Fe3+ and produce OH-, causing DNA single-strand break, preventing DNA replication and interfering with cell division and proliferation in the body. OH- can also directly damage cell membranes, leading to vascular endothelial cell damage, forming sterile inflammation, leading to thickening of the vessel wall and occlusion of the lumen, and vascular endothelial damage can also initiate coagulation mechanisms, leading to thrombosis. Another study showed that Pingyangmycin also has the effect of inducing apoptosis in tumor cells. Therefore, Pingyangmycin can inhibit endothelial cell proliferation, which leads to the treatment of hemangioma; while for low-flow vascular malformations, the accumulation of Pingyangmycin in the tumor body for a longer period of time and at high concentrations causes the lesion to sclerosis and atrophy by damaging the vascular endothelium. Pingyangmycin is a cell cycle non-specific drug, which has less effect on the immune function of the body, no significant effect on hematopoietic function, and few adverse reactions at safe doses. The main complications of previous Pingyangmycin injections are local ischemic necrosis caused by improperly controlled injection volume, complications of infection, and misembolization of other organs leading to vital organ dysfunction, and some reports of cerebral embolism, pulmonary embolism or liver and kidney damage. The ultrasound-guided injection of pinyamycin can display the two-dimensional morphology of hemangioma and clearly show the infiltration range, and the ultrasound-guided injection of polyglaucine can select the best injection site and inject the drug directly and evenly into the lesion area, so as to maintain a long-lasting and high drug concentration in the lesion area and achieve the therapeutic purpose, and at the same time avoid the disadvantages of “blind puncture At the same time, the disadvantages of “blind puncture” are avoided, and the chance of accidental injection into normal tissues is greatly reduced, which significantly reduces the occurrence of adverse reactions. The application of ultrasound in the treatment of hemangioma and vascular malformation has the following advantages: (1) Sonography can identify hemangioma and vascular malformation, clarify the nature of the lesion, and provide a basis for drug allocation and injection method selection; (2) The dose of drug to be injected can be estimated according to the area and volume of the lesion, and the injection site can be precisely located according to the lesion site and characteristics; (3) Multi-point injection under ultrasound guidance can enable the drug to be uniformly distributed in the tumor, and the drug can be injected into the tumor. (3) Ultrasound-guided multi-point injection can distribute drugs evenly within the tumor, avoiding tissue necrosis caused by over-injection at one point and lesions remaining in other parts of the lesion due to insufficient drugs and poor efficacy; (4) For lesions with deeper locations or special sites, ultrasound-guided puncture injection can avoid important vessels, nerves, tendons and other important tissues, reducing the chance of tissue damage and the occurrence of serious complications; (5) Hemangiomas and vascular malformations If incompletely treated, they are highly prone to recurrence. Ultrasound exploration of residual lesions and targeted precise treatment will greatly reduce the recurrence rate of lesions.